Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Curr Opin Investig Drugs. 2006 Jun;7(6):513-21.

Large- and small-molecule inhibitors of transforming growth factor-beta signaling.

Author information

  • University of California at San Francisco, P.O. Box 0875, Cancer Research Institute, 2340 Sutter Street, San Francisco, CA 94143-0875, USA. rakhurst@cc.ucsf.edu

Abstract

A variety of drugs have been developed to inhibit transforming growth factor (TGF)beta signaling. These drugs have been designed to block TGFbeta synthesis, ligand/receptor binding or receptor kinase signaling. Preclinical studies using TGFbeta inhibitors have demonstrated efficacy in reducing metastasis and have shown improvements in cytotoxic drug delivery. Results of phase I/II clinical trials of TGFbeta inhibitors in patients with glioblastoma suggest improved survival rates compared with conventional chemotherapy. The predominant cellular target, whether cancer or stromal cell, immune cell or angiogenesis, may differ between tumor types. Different individuals may show variable responses to drug therapy dependent on both germline genetic variation and the somatic mutation profile of the tumor. A deeper understanding of these issues will assist in targeting the right patients for such therapy, and in limiting unwanted side effects.

PMID:
16784021
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk